SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients With Advanced Hematological Malignancies
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients with Advanced Hematological Malignancies. ASCO 2013. Abstract | Poster
Clinical and Preclinical Activity of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk of Hematologic Malignancies, Against Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Clinical and Preclinical Activity of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk of Hematologic Malignancies, Against Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASCO 2013. Abstract | Poster
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance. ASCO 2013. Abstract | Poster